Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBT (2022 - 2026)

Centessa Pharmaceuticals has reported EBT over the past 4 years, most recently at -$66.7 million for Q4 2025.

  • Quarterly EBT rose 39.53% to -$66.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$195.7 million through Dec 2025, up 15.97% year-over-year, with the annual reading at -$195.7 million for FY2025, 15.97% up from the prior year.
  • EBT was -$66.7 million for Q4 2025 at Centessa Pharmaceuticals, down from -$54.7 million in the prior quarter.
  • Over five years, EBT peaked at -$24.7 million in Q1 2025 and troughed at -$110.3 million in Q4 2024.
  • The 4-year median for EBT is -$49.3 million (2023), against an average of -$51.4 million.
  • Year-over-year, EBT plummeted 208.97% in 2024 and then soared 39.53% in 2025.
  • A 4-year view of EBT shows it stood at -$43.8 million in 2022, then grew by 18.58% to -$35.7 million in 2023, then plummeted by 208.97% to -$110.3 million in 2024, then soared by 39.53% to -$66.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBT are -$66.7 million (Q4 2025), -$54.7 million (Q3 2025), and -$49.6 million (Q2 2025).